RIO DE JANEIRO, BRAZIL - U.S. biopharmaceutical company Immunome, on Monday, April 26th, reported that its antibody cocktail developed for the treatment of Covid-19 demonstrated efficacy against new variants of the coronavirus.
According to the company, the drug was able to neutralize the variants that have emerged in recent months in Brazil (P.1), the UK (B.1.1.7), South Africa (B.1.351) and California (B.1.427/B.1.429) in pre-clinical tests.
In a statement, Immunome said it plans to file for a regulatory investigation into the cocktail between the end of the second . . .